Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

RPG Life Sciences Limited

RPGLIFE:NSI

RPG Life Sciences Limited

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,621.45
  • Today's Change113.25 / 4.52%
  • Shares traded9.73k
  • 1 Year change+82.43%
  • Beta1.0312
Data delayed at least 15 minutes, as of Nov 01 2024 13:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas, including nephrology, oncology, rheumatology, cardiology, respiratory, nutritional, gastroenterology, and diabetology, among others. The International Formulations business operates in the generics and branded generics space across regulated and emerging markets. Its products include Azoran, Mofetyl, Arpimune ME, Azathioprine, Nicorandil, Quinfamide, Nicorandil, Haloperidol, Risperidone, Tolvaptan, Spironolactone, Sertraline, Lamotrigine, and others.

  • Revenue in INR (TTM)6.00bn
  • Net income in INR923.20m
  • Incorporated2007
  • Employees1.27k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SMS Pharmaceuticals Ltd7.38bn569.64m24.93bn1.20k43.63--28.023.386.756.7587.48--------6,168,549.00--5.43--7.3330.1233.307.697.87--4.21--6.1735.868.81805.824.478.419.86
Indoco Remedies Ltd17.73bn320.40m28.60bn5.93k93.032.6320.981.613.343.34175.26118.230.81941.524.512,989,727.001.366.881.999.8568.3465.591.666.930.81421.710.433914.028.9113.41-30.78--34.5437.97
Dishman Carbogen Amcis Ltd24.16bn-2.48bn30.54bn1.13k----176.821.26-15.81-15.81154.06--------21,344,260.00---0.3986---0.488879.3073.83-10.27-1.54---0.7216----8.414.91-414.93---0.3175--
RPG Life Sciences Limited6.00bn923.20m41.48bn1.27k44.93--37.556.9255.8255.82362.60--------4,721,969.00--16.07--21.7768.4262.9915.3911.99--220.43--29.2713.5012.0129.6051.9828.6046.14
Solara Active Pharma Sciences Ltd12.22bn-5.36bn42.96bn2.16k--2.57--3.52-137.13-137.13320.29301.630.47311.772.695,667,023.00-20.76-2.44-36.40-3.8438.7041.16-43.89-4.490.448-1.300.4355---10.73-1.45-2,458.12---4.81--
Jeena Sikho Lifecare Ltd-100.00bn-100.00bn43.37bn1.23k--137.18----------12.72------------------------0.8228--0.2681--43.84--77.37------
Morepen Laboratories Ltd17.45bn1.18bn43.77bn1.62k34.57--29.252.512.312.3134.26--------10,749,300.00--7.90--13.3437.8633.346.775.49--33.34--0.0019.2517.08148.6327.2247.03--
Gufic BioSciences Ltd8.14bn863.69m43.97bn1.45k50.41--42.505.408.708.7081.95--------5,624,707.00--11.46--19.2152.3945.7910.6010.46--8.09--1.3116.8018.128.0731.4653.8314.87
Aarti Drugs Ltd23.80bn1.52bn44.19bn1.06k29.133.4621.491.8616.6216.62259.74139.960.99543.163.4322,364,630.006.379.739.6215.7834.6022.236.408.251.016.830.3159---6.9010.133.0713.8224.96--
Innova Captab Ltd11.42bn1.06bn44.50bn--32.82--35.813.9023.6923.69236.62------------10.82--18.3833.3825.189.308.04--8.89----16.7224.9038.8436.55104.14--
SeQuent Scientific Ltd14.27bn54.87m45.44bn1.20k853.41--58.503.190.21370.213757.18--------11,939,190.00--1.09--1.7645.3841.970.99021.18--0.9009--35.06-3.605.6870.40--6.96--
Hikal Ltd18.03bn677.82m46.93bn2.06k69.28--24.772.605.495.49145.97--------8,749,879.00--5.07--7.5153.0646.783.765.86--2.45--12.19-11.792.34-11.20-7.559.720.00
Supriya Lifescience Ltd6.25bn1.58bn50.18bn448.0031.915.5428.718.0319.5419.5477.55112.560.67372.016.5613,950,510.0016.9819.0818.3824.0466.8157.1225.2024.714.05111.460.0062.8823.7415.4732.5624.7583.79--
Aarti Pharmalabs Ltd19.68bn2.28bn57.96bn1.63k25.413.1218.882.9525.1625.16217.12204.880.77331.624.5912,095,750.008.96--11.86--45.56--11.59--0.961117.120.1723---4.76--12.10------
Data as of Nov 01 2024. Currency figures normalised to RPG Life Sciences Limited's reporting currency: Indian Rupee INR

Institutional shareholders

3.26%Per cent of shares held by top holders
HolderShares% Held
Mirae Asset Investment Managers (India) Pvt Ltd.as of 30 Sep 2024261.06k1.58%
quant Money Managers Ltd.as of 30 Sep 2024166.16k1.01%
Maybank Asset Management Sdn. Bhd.as of 31 Jul 202442.80k0.26%
Union Asset Management Co. Pvt Ltd.as of 30 Sep 202428.89k0.18%
American Century Investment Management, Inc.as of 03 Oct 202411.29k0.07%
WhiteOak Capital Asset Management Ltd.as of 30 Sep 20248.89k0.05%
Acadian Asset Management LLCas of 30 Sep 20237.97k0.05%
Dimensional Fund Advisors LPas of 03 Oct 20247.05k0.04%
SSgA Funds Management, Inc.as of 03 Oct 20243.71k0.02%
State Board of Administration of Florida Retirement Systemas of 30 Jun 20242.05k0.01%
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.